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ABSTRACT: Silk has a long track record of clinical use in the human body, and new formulations, including silk nanoparticles,
continue to reveal the promise of this natural biopolymer for healthcare applications. Native silk fibroin can be isolated directly from
the silk gland, but generating sufficient material for routine studies is difficult. Consequently, silk fibroin, typically extracted from
cocoons, serves as the source for nanoparticle formation. This silk requires extensive processing (e.g., degumming, dissolution, etc.)
to yield a hypoallergenic aqueous silk stock, but the impact of processing on nanoparticle production and characteristics is largely
unknown. Here, manual and microfluidic-assisted silk nanoparticle manufacturing from 60- and 90-min degummed silk yielded
consistent particle sizes (100.9−114.1 nm) with low polydispersity. However, the zeta potential was significantly lower (P < 0.05) for
microfluidic-manufactured nanoparticles (−28 to −29 mV) than for manually produced nanoparticles (−39 to −43 mV). Molecular
weight analysis showed a nanoparticle composition similar to that of the silk fibroin starting stock. Reducing the molecular weight of
silk fibroin reduced the particle size for degumming times ≤30 min, whereas increasing the molecular weight polydispersity
improved the nanoparticle homogeneity. Prolonged degumming (>30 min) had no significant effect on particle attributes. Overall,
the results showed that silk fibroin processing directly impacts nanoparticle characteristics.
KEYWORDS: silk fibroin, nanoparticles, molecular weight, biopolymer, biomaterials
■ INTRODUCTION
For millennia, humans have exploited silk for biomedical
applications.1 The outstanding mechanical properties,2 bio-
compatibility, and biodegradation1,3 of silk have been its
critical quality attributes. Silk is produced by various insects
and spiders. However, the unique ability to farm Bombyx mori
silkworms (i.e., sericulture) enables the industrial production
of the common silk. The highly dependable supply chain for B.
mori silk fibroin has supported its widespread use in humans. B.
mori silk is the only silk type approved for routine clinical use
both as a fiber (i.e., sutures and surgical mesh, SERI Surgical
Scaffold) and as a hydrogel (Silk Voice for vocal fold
augmentation, Sofregen Medical inc, Medford, MA, U.S.A.).1
The B. mori silk fibroin protein consists of a light (≈26 kDa)4
and a heavy chain (≈391 kDa)5,6 linked by a single disulfide
bond.7 Unlike the light chain, the heavy chain has a highly
repetitive block copolymer structure consisting of short
hydrophilic amorphous domains and dominating crystallizable
hydrophobic blocks. These hydrophobic blocks typically
contain glycine-X (GX) repeats, where X is alanine (A)
(65%), serine (S) (23%), or tyrosine (Y) (9%) and form
extensive β-sheet structures.5,6 The β-sheet structures are not
only important for the mechanical properties of silk fibroin but
also contribute to the excellent biocompatibility1,3 of silk while
protecting silk from rapid proteolytic degradation.8
The processing of common silk fibers into a regenerated silk
fibroin protein stock is a well-established practice;9 this
aqueous stock is similar, but not identical, to the native one
present in the silk gland for B. mori silkworms.10 Native silk
fibroin was therefore included in the present study as a control.
Our ability to reverse-engineer the B. mori silk cocoon has
enabled the development of new silk formats.9 Examples
include films, scaffolds, hydrogels, and micro- or nano-
Received: February 9, 2020
Accepted: April 6, 2020
Articlepubs.acs.org/journal/abseba
© XXXX American Chemical Society
A
https://dx.doi.org/10.1021/acsbiomaterials.0c00202
ACS Biomater. Sci. Eng. XXXX, XXX, XXX−XXX
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
86
.4
.2
20
.2
21
 o
n 
M
ay
 5
, 2
02
0 
at
 0
8:
03
:3
0 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
particles.11 Silk has persistently shown biocompatibility,
biodegradation, and mechanical robustness across many
different biomedical applications.1,3 For example, silk nano-
particles are emerging as interesting drug-delivery plat-
forms12,13 and have been earmarked for systemic applications,
including active solid tumor targeting.14 A broad range of silk
nanoparticle manufacturing methods have been explored
(reviewed in15), for example, emulsification (170 nm),16
poly(vinylalcohol) blending (300 nm to 20 μm),17 salting
out (480 nm to 1.2 μm),18 supercritical CO2 (50−100
nm),19,20 and nanoprecipitation using organic solvents (50−
300 nm).21−23 Nanoprecipitation is an easy and robust method
of manual-based nanoparticle manufacturing, although micro-
fluidic manufacturing routes are now being explored to
optimize process control, reduce wastage, and enhance product
quality and consistency.24 Microfluidics has been used to
generate recombinant spider silk microparticles (e.g., ref 25).
We24 as well as others18,26,27 have recently applied micro-
fluidic-based approaches to tune both recombinant and silk
fibroin nanoparticle manufacturing. Silk fibroin nanoparticles
have demonstrated a desirable performance profile, including
low blood coagulation,28 metabolic rewiring,29 and differential
macrophage activation.30 Silk nanoparticles also improved drug
delivery into drug-resistant cancer cells via endocytosis-
mediated uptake22 and default trafficking, resulting in
lysosomotrophic drug release31 in response to low pH and
lysosomal enzymes.8 Now, in silico modeling32 and wet lab
experiments33 are unraveling drug-silk interactions. Our ability
to process silk fibroin under mild conditions and exploit silk
self-assembly, thus eliminating the need for chemical cross-
linkers, is important for the design of silk nanomedicines.15,34
The capacity of silk fibroin to protect liable payloads from
degradation singles this biopolymer out from many other
(bio)polymers.35,36
Formation of the regenerated silk fibroin protein stock
requires sericin removal (i.e., degumming),9 which is an
essential step to yield hypoallergenic silk fibroin.1 The most
common degumming method is the use of alkaline solutions at
high temperatures.9 Next, the extracted silk fibers are dissolved
using a chaotropic agent (e.g., LiBr), or as recently published,
in melted ionic liquids in combination with harsh ultra-
sonification37 to dismantle higher-order silk fibroin structures.9
During degumming and, to a lesser extent, during dissolution
in chaotropic agents, fragmentation of the silk protein
backbone occurs,38 reducing the molecular weight and
subsequently increasing the polydispersity of the biopoly-
mer,39,40 with studies reporting the consequences on
mechanics, self-assembly,40 degradation,41 and drug release.42
However, the impact of silk fibroin stock heterogeneity on
nanoparticle characteristics remains poorly understood, and
Figure 1. Impact of degumming time and manufacturing method on nanoparticle characteristics. (A) Schematic overview of the silk nanoparticle
manufacturing process with either the manual or microfluidic setup. Top row: steps for reverse-engineered silk solution. Bottom row: native silk
extraction and preparation of stock solution. Red boxes indicate that the process parameters varied. This panel was created with BioRender.com.
(B) Qualitative assessment of nanoparticles with SEM (scale bar: 1 μm). (C) Quantitative nanoparticle assessment of size, polydispersity, and
surface charge (n ≥ 3).
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the molecular weight composition of silk nanoparticles is
unknown. The influence of the silk fibroin stock during manual
or microfluidic desolvation also requires investigation to
determine if this influences the physical properties of the
resulting silk nanoparticles. Therefore, this study addressed
these issues by tuning the silk stock processing parameters and
the method of desolvation to assess the impact on the silk
nanoparticle secondary structure, zeta potential, size, compo-
sition, morphology, and cytotoxicity.
■ EXPERIMENTAL SECTION
Extraction of B. mori Silk and Silk Solution Preparation.
Reverse-Engineered Silk Fibroin. Silk from B. mori cocoons was
extracted as described elsewhere;9 a video format has been reported
previously.43 Briefly, B. mori cocoons were cut and boiled in 0.02 M
Na2CO3 solution for either 10, 30, 60, or 90 minutes. The degummed
silk was washed with ultrapure water, air-dried, and dissolved in 9.3 M
LiBr solution for up to 4 h at 60 °C. The resulting solution was
dialyzed (molecular weight cutoff 3500 Da, Thermo Fisher Scientific,
Waltham, MA, U.S.A.) against ultrapure water for 72 h to remove the
LiBr salt.
Native Silk Fibroin. Silk fibroin subjected to minimal processing
was directly isolated from the silk gland. Briefly, B. mori silkworms in
the fourth instar were purchased (Silkwormstore Ltd., London, U.K.)
and reared on reconstituted mulberry leaves at 32 °C with a 12 h
day−night cycle. Native silk was isolated from the gland of B. mori
silkworms in the fifth instar that had started to spin.44 Silkworms were
anesthetized by placing them on ice; they were decapitated, and the
gland was removed. The gland section between the sericin-free
posterior and the posterior median section was cut and transferred
into ice-cold ultrapure water. Next, the epithelium was peeled off
under a stereomicroscope with forceps. The contents were washed
three times for 45 min with ultrapure water to remove residual sericin,
diluted in 1 mL ultrapure water, and kept at 4 °C overnight. This silk
stock was denoted as native silk. The silk concentration was
determined gravimetrically by lyophilizing a known volume of the
solution and measuring the resulting dry weight.
Preparation of Silk Nanoparticles. Silk nanoparticles were
produced by nanoprecipitation using either a manual process22 or a
microfluidic setup24 (Figure 1a). First, the silk solutions from B. mori
cocoons were diluted to 3% w/v with ultrapure water. Native silk
solutions had a high viscosity and were, therefore, diluted to 0.25% w/
v to allow handling during nanoparticle production. For the manual
setup, the silk solution was added dropwise to isopropanol (99.5%,
Ph. Eur) at a volume ratio of 5:1 (i.e., final isopropanol to silk solution
ratio). The microfluidic-assisted setup was a NanoAssemblrTM
benchtop instrument (version 1.5, model number: SN: NA-1.5-16)
(NanoAssemblrTM, Precision Nanosystems Inc. Vancouver, Canada)
equipped with a microfluidic cartridge (product code: NIT0012)
(Precision Nanosystems). A total flow rate of 1 mL min−1 at a volume
ratio of 5:1 of isopropanol to silk was used. The volumes were kept
equal for the manual preparation process. To ensure proper mixing
and nanoparticle formation, 350 μL at the beginning and 50 μL at the
end of the process were discarded. The resulting nanoparticle
suspensions were centrifuged at 48,400g for 2 h; the supernatant was
aspirated, and the residue was resuspended in ultrapure water by
sonicating twice for 30 seconds at 30% amplitude (Sonoplus HD
2070 ultrasonic probe, Bandelin, Berlin, Germany). These steps were
repeated twice. After the final centrifugation, a concentrated silk
nanoparticle suspension was prepared by resuspending the residue in
4 mL of water. The particles were stored at 4 °C until use.
Characterization of Silk Nanoparticles. The yield of nano-
particles was determined by generating a standard curve of absorbance
to mass for each formulation. A dilution series for each nanoparticle
suspension was prepared, and the absorbance was measured at 600
nm (POLARstar Omega, BMG Labtech GmbH, Germany). Next, a
known volume of silk suspension was lyophilized, and the mass of the
dried residue was determined gravimetrically to relate the measured
absorbance to mass. By taking into account the concentration and
volume of the silk solution used, the yield of nanoparticles was
calculated. The particle size and zeta potential were studied as
detailed elsewhere.45 Briefly, the particles were diluted in ultrapure
water and measured by dynamic light scattering (DLS, Zetasizer
Nano-ZS Malvern Instrument, Worcestershire, U.K.) using refractive
indices of 1.33 and 1.45 for ultrapure water and protein, respectively.
Scanning Electron Microscopy. Scanning electron microscopy
(SEM) was used to visualize the morphology of the nanoparticles.
Lyophilized silk nanoparticles were resuspended in distilled water to a
concentration of 1 mg mL−1. The samples were then pipetted onto a
silicon wafer and lyophilized overnight. The specimens were sputter-
coated with 15 nm of gold using an ACE200 low vacuum sputter
coater (Leica Microsystems, Wetzlar, Germany) and analyzed with an
FE-SEM SU6600 (Hitachi High Technologies, Krefeld, Germany) at
5 kV. The SEM images were processed using ImageJ v1.52n (National
Institutes of Health, Bethesda, MD, U.S.A.).
Silk Primary Structure Analysis. The silk protein size
distribution was assessed using sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). Lyophilized silk nanoparticles were
dissolved in 9.3 M LiBr solution at 60 °C and dialyzed (molecular
weight cutoff 3500 Da) against ultrapure water for 24 h to remove the
LiBr salt. Laemmli sample buffer and β-mercaptoethanol (Bio-Rad
Laboratories, Inc., Hercules, CA, U.S.A.) were added, and the samples
were reduced for 10 min at 70 °C and loaded onto 4 to 20% Mini-
PROTEAN TGX precast gels (Bio-Rad Laboratories). The gels were
run with trisglycine SDS running buffer under reducing conditions.
Spectra Multicolor High Range Protein Ladder (Invitrogen, Carlsbad,
CA, U.S.A.) was run as a molecular standard. The gels were stained
with a SilverXpress Silver Staining Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Images were acquired with an 8 megapixel
Wileyfox Swift 2 plus phone, and the pixel density was analyzed by
ImageJ v1.52n (National Institutes of Health, Bethesda, MD, U.S.A).
The vertical profile was plotted against the distance in pixels using
OriginPro2018b software (OriginLab Corporation, Northampton,
MA, U.S.A.).
Secondary Structure Analysis of Silk Nanoparticles. The
secondary structure of silk nanoparticles was examined using Fourier
transform infrared (FTIR) spectroscopy. Silk nanoparticles were
lyophilized before measurement to remove water. Native silk solution
was air-dried prior to measurement. As reference controls, silk films
were used that were either air-dried (low β-sheet content) or
autoclaved to induce high β-sheet content. For all measurements, 128
scans were acquired at a resolution of 4 cm−1 over a 400 to 4000 cm−1
wavenumber range using a PerkinElmer Spectrum 100 instrument
(PerkinElmer, Waltham, MA, U.S.A.). The measured interferogram
was transformed into a spectrum by Fourier transformation. The
spectra were normalized and analyzed with OriginPro2018b software
by peak-fitting the amide I region as shown elsewhere.46 Briefly, the
baseline was subtracted, and the full peak width at half-maximum was
fixed at a constant value to resolve overlapping bands and avoid
overfitting. The amide I region was identified (1595−1705 cm−1) and
fitted by using 11 peaks centered around 1611 cm−1 as a tyrosine side
chain, 1619, 1924, 1630, and 1698 cm−1 as a β-sheet structure, 1640
cm−1 as a random coil structure, 1659 cm−1 as an α-helical structure,
and 1666, 1680, and 1691 cm−1 as a β-turn structure. The relative
areas of the fitted peaks were used to determine the composition of
the secondary structure (Figure S3).
In Vitro Cytotoxicity of Silk Nanoparticles. The mouse
macrophage cell line RAW264.7 (ATCC, Manassas, VA, U.S.A.)
was cultured in Dulbecco’s modified Eagle’s medium (4.5 g glucose,
110 mg sodium pyruvate) supplemented with 10% v/v fetal bovine
serum, 50 U mL−1 penicillin, and 50 μg mL−1 streptomycin (Thermo
Fisher Scientific, U.K.). Cultures were maintained in a humidified 5%
CO2 atmosphere at 37 °C and cultured on tissue culture-treated
polystyrene (Corning, New York, NY, U.S.A.). The cells were
subcultured every 2−3 days (80% confluency) by scraping. For
cytotoxicity assays, the cells were seeded into 96-well plates at a
density of 1.5 × 104 cells per cm2 and allowed to recover overnight.
Next, the medium was removed and replaced with a fresh medium
containing silk nanoparticles (concentration range 2.5−250 μg mL−1).
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The cells were incubated for 48 h, and then 20 μL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (5 mg mL−1 in
phosphate-buffered saline) was added to each well, and the cells were
incubated for an additional 5 h. The supernatant was aspirated, the
formazan crystals were dissolved in 100 μL dimethyl sulfoxide, and
the absorbance was measured at 570 nm. Cell viability was calculated
as a percentage by normalizing to the untreated control population
(i.e., zero nanoparticle dose).
Statistical Analyses. Data were analyzed using OriginPro2018b.
One-way analysis of variance followed by Bonferroni’s post hoc test
was conducted between multiple groups. Sample pairs were analyzed
by either a paired or unpaired t-Test. Normality and homogeneity of
variances were assumed. Asterisks denote statistical significance as
follows: *P < 0.05, **P < 0.01, and ***P < 0.001. All data are
presented as mean values ±standard deviation, and the number of
independent experiments (n) is noted in each figure legend.
■ RESULTS
Nanoparticle Morphology, Size, and Surface Charge.
Silk nanoparticle morphology was analyzed using SEM. All
particles prepared from degummed silk had a spherical shape
(Figure 1b). Stocks of 60- or 90-min degummed silk resulted
in the most uniform particles independent of the manufactur-
ing approach. These results correlated well with quantitative
measurements using DLS (detailed below). The use of native
silk for particle formulation led to irregularly shaped particles
that appeared to aggregate and showed wide size distributions
as quantified with DLS. The largest nanoparticles (196.8 nm)
were obtained when using native silk (i.e., 0 min of
degumming). The particle size decreased with 10 min of
degumming time (167.7 nm) and ranged between 96.9 and
114.1 nm when using longer degumming times (30−90 min)
(Figure 1b). However, polydispersity was the highest for 10-
and 30-min degumming times (0.195−0.217), whereas the
particles showed narrower size distribution for degumming
times of 60 and 90 min with a polydispersity index of 0.088
and 0.107, respectively (Figure 1c). Microfluidic manufactur-
ing, compared to the manual method, showed no substantial
differences in size or polydispersity, whereas the surface charge
decreased from −39 and −43 mV to less negative values (−28
and −29 mV) for 60- and 90-min degummed silks, respectively
(Figure 1c). Across all processing conditions and silk stocks,
the particle size ranged from 96.9 to 196.8 nm with a
polydispersity index between 0.088 and 0.270. All particle
formulations showed a negative surface charge, ranging from
−24 to −43 mV (Figure 1c). Overall, yields ranged from
approximately 8% to 25%; higher yields were observed for
longer degummed silks (Figure S2). For 10-min degummed
silk, both manual and microfluidic manufacturing had low
yields (approximately 8%). The microfluidic-based method
showed a significantly improved yield for 30-min degummed
silk when compared to the manual method (8 vs 17%). For
both 60- and 90-min degummed silk, yields were further
improved (ranging between 19 and 25%) but was the best for
the manual method.
Secondary Structure Analysis of Silk Films and
Nanoparticles. The secondary structure was analyzed using
FTIR spectroscopy and peak fitting of the amide I region.
Native silk obtained from the silkworm gland and air-dried silk
(60-min degumming time) showed a characteristic peak at
higher wavenumbers, indicating higher content of random coil
structures (Figure 2a). In contrast, autoclaved silk and
nanoparticles made with 60-min degummed silk showed a
band between 1622 and 1627 cm−1, which is characteristic of
the antiparallel β-sheet structure. These results correlated well
with the secondary structure analysis after peak fitting (Figure
2b). Silk nanoparticles typically showed higher β-sheet (45−
50%) and lower random coil content (21−23%) compared to
native silk (34% β-sheet and 29% random coil). Using 10-min
degummed silk generated nanoparticles with lower β-sheet
content (45%) compared to the other nanoparticle formula-
tions. All other degumming times showed no substantial
differences between the samples (Figures 2 and S4). There was
no significant difference in the secondary structure for batch or
microfluidic manufactured silk nanoparticles.
Fragmentation of the silk fibroin during the degumming
process was analyzed using SDS-PAGE. The isolated native silk
stock (i.e., 0 min of degumming) showed two major bands
likely indicating the heavy chain (360 kDa) and light chain (26
kDa) of the silk fibroin (Figure 3a). With increasing
degumming time, the clear bands at 360 and 26 kDa
disappeared and were no longer visible at degumming times
above 60 min. Furthermore, all degummed samples showed
protein smearings that were shifted toward lower molecular
weights with increasing degumming time. These trends were
confirmed using densitometry gel analysis. Here, the
absorbance intensity at 26 kDa decreased, and the overall
intensity broadened with increasing degumming times. The
assembly of silk fibroin fragments into nanoparticles was
analyzed by redissolving silk nanoparticles and subjecting the
extracted silk fibroin to the SDS-PAGE analysis (Figure 3b).
Particles manufactured from native silk showed two main
Figure 2. Secondary structure determination of silk nanoparticles. (A)
FTIR absorbance spectra in the amide I region of nanoparticles
manufactured from 60-min degummed silk with the manual method.
Controls include native silk as well as air-dried and autoclaved silk
film. The dashed line marks the absorption band between 1622 and
1627 cm−1, which is characteristic of the antiparallel β-sheet structure.
(B) Secondary structure content of native silk and silk nanoparticles.
Native silk fibroin was obtained from the silk gland with minimal
processing. Silk nanoparticles were manufactured either manually or
by microfluidics.
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bands similar to those observed for the native silk fibroin stock
solution. The analysis of nanoparticles from 10-min
degummed silk showed a molecular weight distribution similar
to what was observed in the respective stock solutions. At
degumming times above 30 min, the silk fibroin band at 360
kDa disappeared completely from the silk fibroin stock;
disassembly of the respective nanoparticles and analysis of the
silk fibroin content showed no substantial differences between
the starting stock and the incorporated silk fibroin fragments.
There were no apparent differences in the silk incorporated
into the nanoparticles generated using either manual or
microfluidic-assisted manufacturing.
In Vitro Cytotoxicity of Silk Nanoparticles. Cell
viability of RAW 264.7 cells was analyzed using nanoparticle
concentrations ranging from 2.5 to 250 μg mL−1 (Figure 4).
The half-maximal inhibitory concentration (IC50) was >250 μg
mL−1 for all formulations. Up to a concentration of 100 μg
mL−1, the degumming time and the manufacturing method
Figure 3. Analysis of silk fibroin fragmentation and assembly into nanoparticles. SDS-PAGE (right) and densitometry analysis (left) of (A) silk
stock solutions prepared from native and degummed B. mori silk and (B) analysis of the silk incorporated into nanoparticles manufactured manually
or by microfluidics.
Figure 4. In vitro cytotoxicity of silk nanoparticles in macrophages. RAW 264.7 cells were exposed for 48 h to 2.5−250 μg mL−1 nanoparticles
prepared from 10-, 30-, 60-, or 90-min degummed silk. Nanoparticles were manufactured using either a (A) manual or (B) microfluidic method. (n
= 3).
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had no substantial effect on the cell viability. Overall, all
formulations showed good biocompatibility in RAW 264.7
cells up to a concentration of 100 μg mL−1 (cell viability >
75%).
■ DISCUSSION
Silk is now making inroads as a biopolymer for drug delivery
across different material formats, including particles.34 A wide
spectrum of manufacturing methods has been reported
yielding silk particles ranging from the nano- to the
microscale.12,15 For example, exploring the innovative use of
ionic liquids.37 While the optimum particle size is application-
dependent, particles in the nanometer size range permit first-
to third-order targeting. For example, nanoparticles adminis-
tered systemically have the potential to exploit leaky blood
vessels that, in turn, facilitate the exit of nanoparticles from
circulation and accumulation in the extracellular space and the
subsequent entry of the nanoparticles into cells through
endocytosis and lysosomal trafficking.13,47 The potential of
tissue targeting of the payload and particle-mediated changes
of cellular uptake mechanisms is exciting because they now
provide a route to overcome delivery barriers for a broad range
of payloads.48 However, the manufacture of these particles to a
clinical standard is challenging, and improved production
routes are needed.49,50 For example, the pharmaceutical
industry is currently shifting from batch to continuous
manufacturing in an effort to reduce manufacturing error,
reduce contamination risk, and maximize production yields.51
Microfluidics is one such tool that is being adopted by the
industry and hence included in the present study.
Our knowledge of silk processing parameters and the
consequences on particle attributes is limited. One fundamen-
tal factor is silk degumming. To reflect current practices, we
selected the commonly used sodium carbonate degumming
process exploring a 10- to 90-min degumming time followed
by the lithium-bromide silk fibroin dissolution protocol.9
Nanoparticles of similar sizes were obtained (96.9−122.4 nm)
for a degumming time of 30−90 min using both microfluidic
and manual-based production processes. This particle size is in
good agreement with previous reports,22,43,45 although we
observed a comparatively large particle size for 10-min
degummed silk (167.7 nm) and increased polydispersity for
the 10- and 30-min degummed samples. To differentiate, if this
was due to silk fibroin stock attributes or the particle
production process, we conducted pilot studies using our
microfluidic setup (Figure S1, Supporting Information). Using
microfluidics, the 10-min degummed silk fibroin yielded the
largest silk nanoparticles (219.8 nm) with a comparatively high
polydispersity. We therefore concluded that the silk fibroin
stock critically influenced the size and sought to extract
monodispersed silk fibroin directly from the glands of B. mori
silkworms to be used in manual nanoparticle manufacturing.
Native silk fibroin generated large silk nanoparticles (196.8
nm) with the highest polydispersity (0.270) and a significantly
(P < 0.001) reduced surface charge when compared to 60-min
degummed silk (−24 vs −39 mV). The native silk fibroin stock
was diluted to reduce solution viscosity and improve handling.
However, attempts to use this stock with our microfluidic
setup resulted in catastrophic chip fouling; therefore, no
preliminary data are available. Therefore, we decided not to
further explore the native silk in the microfluidic setup because
of the processing challenges but instead focus on reverse-
engineered silk. We note that Holland and co-workers have
successfully used native silk fibroin feedstocks in combination
with microfluidics to create a microparticle library.44 We
believe that microfluidic geometries and processing conditions
are critical when working with native silk fibroin.
All nanoparticles manufactured in the present study were
subjected to surface charge measurements. All current baseline
measurements were conducted in water to minimize
cofounding effects (e.g., aggregation). However, future studies
exposing silk nanoparticles to buffered solutions could provide
useful information to uncover further structural details. Manual
manufacturing using 60- or 90-min degummed silk resulted in
the most negative zeta potential values (−39 to −43 mV)
similar to previous data.22,43,45 However, 10- and 30-min
degummed silk yielded significantly (P < 0.001) lower surface
charges (−28 and −28 mV, respectively). These values were
closest to the zeta potential of native silk fibroin nanoparticles.
Switching from manual to microfluidic-assisted production
significantly (P < 0.05) reduced the zeta potential of 60- and
90-min degummed silk nanoparticles to values similar to those
of 10- or 30-min degummed silk (Figure 1d), an important
observation. These data suggest that the microfluidic setup
generated nanoparticles that had a different silk fibroin packing
geometry with more of the ionizable acidic functional groups
hidden from the nanoparticle surface, albeit with a similar
secondary structure (discussed below). This observation is
surprising, and we speculate that the herringbone structure of
the microfluidic chip allows for chaotic and rapid mixing,52
yielding silk nanoparticles with different surface characteristics.
However, the exact mechanism of silk nanoparticle formation
is currently unknown. Imaging showed that all processed
samples contained nanoparticles, albeit with differences in
appearance. Native silk fibroin nanoparticles showed a globular
configuration with extensive cohesion and a “sticky” appear-
ance that was less prominent for 10-min degummed samples
and absent for all other nanoparticles. Degumming for 30 min
and more resulted in a narrow particle size distribution and an
appearance identical to those reported previously. Nano-
particle yields for identical degumming times were similar for
both manual and microfluidic processed particles (Figure S2).
A notable exception was 30-min degummed silk with
microfluidic processing doubling the yield; the underlying
reason for this is currently not known.
Secondary structure analysis revealed that both microfluidic
and manually produced silk fibroin nanoparticles had a similar
conformation; there were little differences in the secondary
structure across the entire silk nanoparticle library. Both the
production methods exposed silk nanoparticles to isopropanol.
Isopropanol crystallizes silk, which is thereby expected to
maximize the amount of β-sheets present in the secondary
structure (Figure 2). However, in the absence of such a
solvent, it is plausible to speculate that nanoparticles with an
amorphous structure can be generated (e.g., ref 53) by
exploiting the silk fibroin natural micellar conformation.
However, amorphous silk nanoparticles are predicted to have
a poor shelf life and are thus of limited value for
pharmaceutical applications. The native silk stock showed
substantially lower crystallinity than samples exposed to
isopropanol. However, we observed a β-sheet content of
>30% which is higher than that reported in the literature (e.g.,
ref 54). Secondary structure composition of native silk fibroin
is easily influenced not only by its environment such as
surrounding pH and salt concentration but also by mechanics
such as shear stress and drying.55,56 This responsiveness can
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complicate the sample assessment but can also make silk
fibroin a versatile material that is amenable to precise
secondary structure tuning.57 Further evidence of process-
dependent secondary structure tuning comes from experiments
with the native silk fibroin stock. Here, different micrometer-
sized silk constructs were manufactured using microfluidics;
some of these shapes were highly amorphous.44
Contrary to our assumption that a narrow silk fibroin
polydispersity would lead to a narrow particle size distribution,
particle size control was the best at the 60- and 90-min
degumming times. In contrast, a relatively large nanoparticle
polydispersity was observed for the native silk fibroin stock
despite the stock being essentially monodispersed. Seminal
work by Carissimi and coworkers also suggests that a reduction
in the molecular weight results in more uniform silk fibroin
nanoparticles.58 Besides particle uniformity, the particle size
was also monitored. Silk degummed for only 10 min yielded
the largest nanoparticles (167.7 nm) and were most similar to
those generated from the native silk fibroin stock (largest
nanoparticles reported in this study). In contrast, degumming
times of 30 min and longer consistently yielded silk
nanoparticles in the 100 nm size range. This observation is
in agreement with previous studies where a reduced silk fibroin
molecular weight yielded smaller particles;59 our preliminary
studies22 and work by Carissimi58 have corroborated these
findings.
Commonly used silk degumming and dissolution pro-
cesses38 damage the silk fibroin structure, resulting in a
reduction in the molecular weight and increased polydispersity.
We used sodium carbonate because it is widely used, effectively
removes sericin, and results in up to 40% greater molecular
weight reduction than sodium bicarbonate38 or urea.39 SDS-
PAGE analysis indicated boiling time-dependent silk fibroin
fragmentation of both light and heavy chains, confirming
earlier reports.40 It is reasonable to speculate that the silk
fibroin molecule does not undergo random molecular weight
reduction except at key locations that are most susceptible. For
example, the completely amorphous nature of a silk light chain
renders this site most vulnerable to degradation as also the
single disulfide bond between the light and heavy chains.7 The
amorphous segments within a silk heavy chain are also
expected to be damaged during degumming, whereas the silk
crystalline domains are expected to last. SDS-PAGE analysis
supports this sequence of events. SDS-PAGE analysis of 10-
min degummed silk fibroin showed a prominent band at
approximately 25 kDa, which was essentially absent at 30 min.
It is plausible that this band is the liberated silk fibroin light
chain. An alternative explanation could be that this band is the
p25 glycoprotein fibrohexamerin (it has a molecular weight
very similar to that of the silk fibroin light chain).5 Irrespective
of the nature of this particular band, longer degumming times
clearly lead to its fragmentation (i.e., disappearance). There-
fore, the presence of this 25 kDa protein could impact particle
formation and ultimately dictate the size. Although SDS-PAGE
analysis of the silk fibroin stocks is important, in isolation, it
provides little information about the actual composition of the
silk nanoparticles. Therefore, silk nanoparticles were dis-
assembled and analyzed with SDS-PAGE. Across all silk fibroin
samples, the nanoparticle composition resembled the starting
stock. There was no apparent preferential incorporation of
protein subsets into the respective nanoparticles. However, silk
nanoparticles generated from 10-min degummed silk had
larger particle diameter (167.7 nm) and polydispersity (0.195)
while containing a 25 kDa protein. One might speculate that
the presence of this 25 kDa protein impacts nanoparticle
characteristics (Figure 3b). Unfortunately, our experimental
design did not allow us to prove this, and hence further studies
are required to extract this 25 kDa band to fully elucidate its
role. In addition to the spectrum of silk nanoparticle
characteristics assessed here, the initial biological response
toward macrophages was assessed too. All silk nanoparticles
were well tolerated with similar results reported previously.29
■ CONCLUSIONS
Overall, this study demonstrates that silk fibroin processing
directly impacts nanoparticle attributes. We employed both
manual and microfluidic-assisted silk nanoparticle manufactur-
ing routes and showed that neither the particle size nor the
secondary structure was affected by the selected production
methods. However, the zeta potential was significantly affected,
and we speculate that microfluidics reduced the surface-
accessible acidic functional groups. SDS-PAGE analysis of the
nanoparticles showed that their composition resembled the silk
fibroin starting stock. Overall, this study provides novel insight
into the processing parameters influencing silk fibroin
nanoparticle performance.
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